Legend Biotech Corp Chief Executive Officer Ingrid Zhang filed a Form 4 on November 20, 2026, disclosing the purchase of 20,000 ordinary shares on November 17, 2026, at a converted price of $8.16 per share.
Key Highlights
- Reporting person: Ingrid Zhang, Chief Executive Officer of Legend Biotech Corp (NASDAQ:LEGN)
- Transaction date: November 17, 2026
- Shares acquired: 20,000 ordinary shares, coded as a purchase (P)
- Purchase price: $8.16 per ordinary share, converted from an ADS purchase price of $16.32 per ADS
- Beneficial ownership following transaction: 1,151,860 ordinary shares held directly
- ADS structure: Each ADS represents two ordinary shares of the issuer
Zhang Ingrid's November 2026 Open-Market Purchase of Legend Biotech Ordinary Shares
According to the Form 4 filed with the SEC on November 20, 2026, Ingrid Zhang, serving as Chief Executive Officer of Legend Biotech Corp, acquired 20,000 ordinary shares of the company on November 17, 2026. The filing identifies the transaction code as "P," indicating an open-market purchase. The price reported in the filing is $8.16 per ordinary share, which the filing describes as the converted purchase price of American Depositary Shares at $16.32 per ADS.
The filing notes that Legend Biotech's ordinary shares may be represented by ADSs, with each ADS representing two ordinary shares of the issuer. Following the reported transaction, Zhang's direct beneficial ownership of ordinary shares stands at 1,151,860, as stated in the filing. No derivative securities transactions were reported in Table II of the form.
The Form 4 was signed by Robert Staloff as Attorney-in-Fact on November 20, 2026. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not selected. Zhang's address of record is listed as c/o Legend Biotech Corp, 77 Corporate Drive, 4th Floor, Bridgewater, New Jersey 08807.
What Was Disclosed
Legend Biotech Corp's CEO Ingrid Zhang reported a direct purchase of 20,000 ordinary shares at $8.16 per share on November 17, 2026, bringing her total direct beneficial ownership to 1,151,860 ordinary shares, according to the Form 4 filed November 20, 2026.



Please wait processing your request...